一、市场规模持续高增，中国稳居第一进口来源
数据显示，巴基斯坦2024年医疗器械市场规模达7亿美元，行业预期市场规模将持续增长至10.2亿美元；国内器械需求年增速稳定在8%-15%，进口来源覆盖全球68个国家，自中国进口器械占全部进口总额40.7%，中国产品在当地市场拥有稳固占有率。
目前巴基斯坦本土持证医疗器械生产商共125家，可自主生产伤口敷料、注射耗材、快速诊断试剂、透析耗材、防护装备、冠脉支架等品类，但高端设备、上游原料仍存在大量进口缺口，市场增量空间充足。
1. The market size continues to grow rapidly, with China firmly remaining the top import source.
Data shows that Pakistan's medical device market is expected to reach USD 700 million in 2024, with industry forecasts suggesting it will continue to grow to USD 1.02 billion. Domestic demand for medical devices has an annual growth rate of 8%-15%, with imports coming from 68 countries worldwide. Imports from China account for 40.7% of the total, and Chinese products hold a stable market share locally.
Currently, there are 125 licensed domestic medical device manufacturers in Pakistan, capable of producing wound dressings, injection consumables, rapid diagnostic reagents, dialysis consumables, protective equipment, coronary stents, and other categories independently. However, there remain significant import gaps for high-end equipment and upstream raw materials, leaving ample room for market growth.
二、本土原材料禀赋突出，配套产业链基础扎实
巴基斯坦拥有得天独厚的医疗器械上游原料资源，为本地化生产提供成本优势：
1. 纺织原料：全球第四大棉花生产国，棉花纺织品出口占全国出口总额60%，可支撑纱布、无菌垫、手术单、医用PPE等敷料类产品制造；
2. 金属加工：锡亚尔科特形成成熟精密金属产业集群，适配手术器械、针具、骨科金属设备生产；
3. 精细化工：依托成熟制药产业基础，可供应消毒剂、抗菌剂、透析液等化学耗材原料；
4. 高分子材料：本地企业可供应医用PP、PVC树脂，支撑注射器、输液管路、导管、输液袋等一次性耗材生产。
其中棉花纺织、精密金属加工产业已形成成熟配套，精细化工配套完善，医用高分子材料产业处于快速发展阶段。
2. Local raw materials are abundant, and the supporting industrial chain is solid.
Pakistan has unique upstream raw material resources for medical devices, providing cost advantages for localized production:
1. Textile raw materials: As the world's fourth-largest cotton producer, cotton textile exports account for 60% of the country's total exports, supporting the production of gauze, sterile pads, surgical drapes, medical PPE, and other dressing products;
2. Metal processing: Sialkot has developed a mature precision metal industry cluster, suitable for the production of surgical instruments, needles, and orthopedic metal equipment;
3. Fine chemicals: Relying on a mature pharmaceutical industry base, it can supply raw materials for chemical consumables such as disinfectants, antibacterial agents, and dialysis solutions;
4. Polymer materials: Local companies can supply medical-grade PP and PVC resins, supporting the production of disposable consumables such as syringes, infusion tubing, catheters, and infusion bags.
Among these, the cotton textile and precision metal processing industries have formed mature supporting systems, fine chemical support is complete, and the medical polymer materials industry is in a rapid development stage.
三、三大核心合资赛道，精准匹配中国器械企业优势
DRAP重点推介三类具备高投资回报的合作领域，精准贴合国内医疗器械企业产能优势：
1. 一次性医用耗材合资建厂
涵盖静脉插管、注射器、输液器等产品，依托《AD-注射器政策》形成本土市场保护壁垒，内需稳定；
2. IVD体外诊断与透析耗材合作
国内公共医疗体系对快速检测试剂、透析液需求旺盛，相关产品年进口额达7000万美元，支持中方开展试剂本地灌装、成品加工业务；
3. 高端医疗设备SKD/CKD组装本地化
面向MRI、X光机、监护仪、呼吸机等电子医疗设备，推行零部件散件组装模式，逐步推进全产业链本土化落地，填补本土高端设备产能空白。
III. Three Core Joint Venture Tracks, Precisely Matching the Advantages of Chinese Medical Device Companies
DRAP focuses on promoting three types of high-investment-return cooperation areas, precisely aligning with the production advantages of domestic medical device companies:
1. Joint Venture Production of Disposable Medical Consumables
Covers products such as venous catheters, syringes, and infusion sets, relying on the "AD-Syringe Policy" to establish local market protection barriers, ensuring stable domestic demand;
2. Cooperation in IVD In Vitro Diagnostics and Dialysis Consumables
The domestic public healthcare system has a strong demand for rapid test reagents and dialysis solutions, with related products having annual import amounts reaching 70 million USD, supporting local reagent filling and finished product processing by Chinese partners;
3. Localization of Assembly for High-End Medical Equipment SKD/CKD
Targeting electronic medical equipment such as MRI, X-ray machines, monitors, and ventilators, promoting a component parts assembly model, gradually advancing full industry chain localization, and filling the domestic gap in high-end equipment production capacity.
四、简化全流程审批，注册许可时效大幅压缩
DRAP医疗器械处统一负责器械企业机构许可、产品注册全流程业务，搭建线上数字化申报渠道，审批时限极具竞争力：
1. 企业生产许可（ELM）流程：线上提交申请表→场地现场核验→医疗器械委员会评审→核发生产许可；
2. 进口器械许可（ELI）流程：线上提交材料、仓库核查→委员会评审后签发进口许可；
3. 产品注册流程：线上提交产品资料→专业人员技术评估→委员会审核后发放注册凭证；
4. Simplify the entire approval process, significantly shorten the registration and licensing timeframe
The DRAP Medical Device Department is solely responsible for the full-process services of medical device company institutional licenses and product registrations, establishing an online digital application channel with highly competitive approval timelines:
1. Enterprise Production License (ELM) process: submit application form online → on-site inspection of premises → review by the Medical Device Committee → issuance of production license;
2. Imported Device License (ELI) process: submit materials online, warehouse inspection → issuance of import license after committee review;
3. Product Registration process: submit product information online → technical evaluation by professionals → issuance of registration certificate after committee review;
五、产业合作前景展望
巴方表示，依托中巴经济走廊合作框架，叠加本土原材料、劳动力、政策保护多重优势，巴基斯坦可成为中国医疗器械辐射南亚、中亚市场的核心生产集散基地。DRAP将持续优化医疗器械数字化申报系统，完善评审配套机制，推出更多外资投资便利举措，欢迎中国耗材、IVD、高端医疗设备企业以合资建厂、技术输出、散件组装等多种形式深度布局。
V. Prospects for Industrial Cooperation
The Pakistani side stated that relying on the China-Pakistan Economic Corridor cooperation framework, combined with multiple advantages of local raw materials, labor, and policy protection, Pakistan can become a core production and distribution base for Chinese medical devices radiating to the South Asian and Central Asian markets. DRAP will continue to optimize the digital application system for medical devices, improve the supporting review mechanisms, introduce more measures to facilitate foreign investment, and welcomes Chinese consumables, IVD, and high-end medical equipment companies to deeply engage through joint venture manufacturing, technology transfer, and component assembly in various forms.
茂本公司（中国）是一站式综合经贸服务企业，核心覆盖境内外会展全流程运营、大宗商品双向贸易、全球跨境供应链配套、海外投资项目四大核心业务。
公司依托成熟的海内外产业资源网络，深度联动中国-非洲、中国-巴西、中国-东南亚等市场工商协会、产业园区与政企平台，可为中外企业提供国际展会策划招商、B2B供需对接、粮油/机电/新能源/医药等品类大宗贸易撮合、国际物流清关仓储、海外投资调研、PPP项目规划、外资落地合规代办一体化解决方案，助力国内企业出海拓市，同步引进海外优质农副产品、特色产业资源对华流通，深度服务中巴经济走廊跨境经贸与双边产业合作。
Mallbem Company (China) is a one-stop comprehensive economic and trade service enterprise, with core businesses covering four major sectors: full-process operation of domestic and overseas exhibitions, two-way bulk commodity trade, global cross-border supply chain supporting services, and overseas investment projects.
Relying on a mature network of domestic and international industrial resources, the company deeply connects business associations, industrial parks, and government-enterprise platforms in markets such as China-Africa, China-Brazil, and China-Southeast Asia. It can provide an integrated solution for Chinese and foreign enterprises, including international exhibition planning and investment promotion, B2B supply and demand matching, bulk trade matching in categories such as grain and oil, electromechanical products, and new energy, international logistics, customs clearance and warehousing, overseas investment research, PPP project planning, and compliance services for foreign investment localization. This helps domestic enterprises expand overseas markets while simultaneously introducing high-quality overseas agricultural and sideline products and specialty industrial resources to China, deeply serving cross-border trade and bilateral industrial cooperation along the China-Brazil economic corridor.